A1 Refereed original research article in a scientific journal

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing




AuthorsBrauner Jørgensen, Jacob; Christensen, Karl Bang; Michelsen, Brigitte; Loft, Anne Gitte; Horskjær Rasmussen, Simon; Heberg, Jette; Lund Hetland, Merete; Zavada, Jakub; Pavelka, Karel; Iannone, Florenzo; Conti, Fabrizio; Borges, Joana; Codreanu, Catalin; Mogosan, Corina; Glintborg, Bente; Ciurea, Adrian; Nissen, Michael J.; Nordström, Dan; Kuusalo, Laura; Laas, Karin; Vorobjov, Sigrid; Gudbjornsson, Bjorn; Love, Thorvardur Jon; Østergaard, Mikkel; Ørnbjerg, Lykke Midtbøll

PublisherBMJ Publishing Group

Publication year2025

Journal: RMD Open

Article numbere006104

Volume11

Issue4

eISSN2056-5933

DOIhttps://doi.org/10.1136/rmdopen-2025-006104

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Open Access publication channel

Web address https://doi.org/10.1136/rmdopen-2025-006104

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/508327704

Self-archived copy's licenceCC BY NC

Self-archived copy's versionPublisher`s PDF


Abstract

Objectives:
The Disease Activity index for Psoriatic Arthritis (DAPSA) was developed to assess disease activity in patients with psoriatic arthritis (PsA). A modified version, DAPSA28, uses 28 joints instead of 66/68. This study evaluated key psychometric properties of DAPSA and DAPSA28.

Methods:
Data from 1865 patients with PsA in the European Spondyloarthritis (EuroSpA) Research Collaboration Network, having DAPSA and DAPSA28 scores at baseline and follow-up, were analysed. Tests included assessment of internal construct validity by scree plots, confirmatory factor analysis (CFA) and structural equation modelling (SEM), supplemented by tests of differential item functioning (DIF) and evaluation of internal consistency reliability by Cronbach’s α (CA). A subset of 625 patients was used for most analyses, except descriptive statistics, correlation matrix and CA.

Results:
One-dimensional CFA models for DAPSA and DAPSA28 showed acceptable model fit at baseline (root mean square error of approximation, RMSEA: 0.020, 0.034). However, model fit at 6 months follow-up was poor (RMSEA: 0.057, 0.063). SEM combining baseline and follow-up data could not identify an acceptable model fit. DIF was found for sex and country. CA indicated acceptable internal consistency (DAPSA: 0.65; DAPSA28: 0.63). Heterogeneity across countries was observed.

Conclusions:
Overall, the model fit was acceptable across model fit statistics, supporting internal construct validity, but some evidence of misfit at country level was disclosed. Our findings support acceptable internal consistency reliability, but DIF was found for sex and country. Based on mixed results of model fit and DIF, further investigation of these and other PsA disease activity measures is warranted.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
No financial sponsors had any influence on the data collection, statistical analyses, abstract/manuscript preparation, or decision to submit. The EuroSpA collaboration has been supported by Novartis Pharma AG since 2017 and UCB Biopharma SRL since 2022.


Last updated on 20/01/2026 03:09:04 PM